ストックスクリーナーアプリを入手
8.2012
1.14%
-0.0988
前日終値:
$8.30
開ける：
$8.29
24時間の取引高:
2.25M
Relative Volume:
0.49
時価総額：
$2.53B
収益：
$493.67M
当期純損益:
$-104.69M
株価収益率:
-24.12
EPS:
-0.34
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
+0.55%
1か月 パフォーマンス:
+2.69%
6か月 パフォーマンス:
+26.62%
1年 パフォーマンス:
-21.86%
1日の値動き範囲:
$8.00
$8.37
1週間の範囲:
$8.00
$8.505
52週間の値動き範囲:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
FOLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.20 | 2.56B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.36 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.58 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.96 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.94 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.05 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | アップグレード | Needham | Hold → Buy |
| 2025-07-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Why Amicus Therapeutics Inc. stock is a must watch in 2025Trade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
How to escape a deep drawdown in Amicus Therapeutics Inc.Market Risk Summary & Reliable Intraday Trade Alerts - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryWeekly Stock Report & Community Consensus Stock Picks - newser.com
Can volume confirm reversal in Amicus Therapeutics Inc.Fed Meeting & Fast Gain Stock Trading Tips - newser.com
What earnings revisions data tells us about Amicus Therapeutics Inc.Buy Signal & Technical Pattern Based Signals - newser.com
What Fibonacci levels say about Amicus Therapeutics Inc. reboundPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Will a bounce in Amicus Therapeutics Inc. offer an exitMarket Movers & Risk Controlled Stock Alerts - newser.com
Heatmap analysis for Amicus Therapeutics Inc. and competitorsEarnings Recap Summary & Entry Point Confirmation Signals - newser.com
What macro factors could drive Amicus Therapeutics Inc. (AM6) stock higherJuly 2025 Summary & Accurate Technical Buy Alerts - newser.com
Developing predictive dashboards with Amicus Therapeutics Inc. dataJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
Amicus Therapeutics Inc. stock prediction for this weekMarket Sentiment Report & High Accuracy Swing Trade Signals - newser.com
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesPortfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Real time scanner hits for Amicus Therapeutics Inc. explainedJuly 2025 Selloffs & Verified Entry Point Detection - newser.com
Amicus Therapeutics (NASDAQ:FOLD) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease - Nasdaq
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Q3 EPS Forecast for Amicus Therapeutics Lifted by Analyst - MarketBeat
What Does Wall Street Think About Amicus Therapeutics (FOLD)? - MSN
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy - sharewise.com
Is Amicus Therapeutics Inc AM6 a good long term investmentVWAP Trading Strategies & Consistent Triple Returns - earlytimes.in
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments - Yahoo Finance
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Fore - PharmiWeb.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns - TradingView
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockStop Loss & Weekly High Potential Stock Alerts - newser.com
A Look at Amicus Therapeutics’s Valuation After Analyst Upgrade and Improved Outlook (FOLD) - Yahoo Finance
Is Amicus Therapeutics Inc. (AM6) stock a top pick for value investorsWeekly Volume Report & Fast Gain Swing Alerts - newser.com
Market reaction to Amicus Therapeutics Inc.’s recent newsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
How to forecast Amicus Therapeutics Inc. trends using time seriesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Needham Upgrades Amicus Therapeutics(FOLD.US) to Buy Rating, Announces Target Price $14 - 富途牛牛
Technical signs of recovery in Amicus Therapeutics Inc.2025 Investor Takeaways & AI Driven Price Forecasts - newser.com
Using Ichimoku Cloud for Amicus Therapeutics Inc. technicalsWeekly Profit Recap & Reliable Volume Spike Alerts - newser.com
Can Galafold Drive Amicus' Growth Through the Rest of 2025? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Trading Up 6.5%What's Next? - MarketBeat
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
Amicus Therapeutics Inc (FOLD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
1.24%
大文字化:
|
ボリューム (24 時間):